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Abstract Docking studies were performed to investigate the
binding of several antimalarial compounds to the putative drug
receptors involved in the hematin aggregation process. These
studies reveal a binding pro¢le that correlates with the comple-
mentarity of electrostatic potentials between the receptors and
the active molecules. These results allow a possible explanation
for the same molecular mechanism shown by 4-aminoquinolines,
quinine, me£oquine, halofantrine and hydroxylated xanthones.
The docking data presented in this work o¡er an interesting
approach to the design of new molecules with potential antima-
larial activity.
# 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Malaria is a disease of major relevance in the world, with a
prevalence of 300^500 million clinical cases and 2 million
deaths each year [1]. The loss of e⁄cacy of the available
antimalarial compounds due to drug resistance increases the
concerns about this health problem [1]. The continuing spread
of drug-resistant malaria imposes the need for the develop-
ment of new potential antimalarial molecules. This can be
accomplished with the understanding of the molecular mech-
anisms that can lead to an antimalarial action. One of these
mechanisms is the inhibition of the detoxi¢cation of the heme
released from the hemoglobin digestion [2]. The malaria para-
site has a limited capacity for amino acid synthesis, acquiring
the essential nutrients from hemoglobin proteolysis [2]. This
digestion of hemoglobin releases heme, which oxidizes to
hematin and originates a toxic action against the parasite
[3]. Plasmodial species detoxify by sequestering this by-prod-
uct into a chemically inert crystal of hemozoin, overcoming
the lack of the heme oxygenase, the defensive mechanisms
used by vertebrates [3^5]. Hemozoin is an aggregate of several
units of hematin linked by carboxylate^iron(III) and carbox-
ylate^carboxylate coordinated bonds [6,7].
Several antimalarial compounds interfere in this metabolic
pathway by associating with a derivative form of hematin,
thus avoiding the aggregation of this porphyrin in the hemo-
zoin formation process [8]. This provides a su⁄cient amount
of free hematin to develop an antimalarial action [9]. Thus,
the referred derivative form of hematin constitutes a pharma-
cological receptor of interest.
The most defended possibility is that the derivative form
referred to corresponds to a W-oxo-dimer of hematin
[8,10,11], a complex of two molecules of hematin connected
by an oxygen bridge between the two iron atoms [7].
The de¢nition of the structure of the malaria pigment by
high-resolution X-ray powder di¡raction allowed the estab-
lishment of hemozoin as another possibility for a drug recep-
tor [6,12]. The antimalarial drug action could arise from sur-
face adsorption on the growing hemozoin crystallites, limiting
new hematin uptake [6]. The consequently free hematin would
develop its toxicity against the parasite.
The antimalarial 4-aminoquinolines me£oquine, halofan-
trine and quinine can inhibit parasite growth by preventing
the formation of hemozoin [13^17]. Hydroxylated xanthones
also have shown antimalarial activity, pointing to the same
molecular mechanism [18^21].
Several studies have been performed on antimalarial com-
pounds, relating their activity with their electrostatic potential
[22^26]. We present a study relating di¡erent antimalarial
molecules with the two putative receptors that are involved
in their antiplasmodial action. Electrostatic interactions are
one of the phenomena that rule the association between a
molecule and its receptor. The electrostatic potential pro¢les
determined for the active molecules o¡er a possibility of com-
plementarity with the electrostatic potentials determined for
the two putative receptors. To corroborate our ¢ndings we
have performed docking studies between the referred active
compounds and the putative receptors hematin W-oxo-dimer
and hemozoin. The results obtained agree with the molecular
electrostatic potentials.
2. Materials and methods
Geometry optimizations and energy calculations for all the ligands
in the neutral form were performed at an ab initio quantum mechan-
ical level by using density functional theory (DFT) with the Becke3^
Lee^Yang^Parr (B3LYP) functional, and the 3-21G basis set, fol-
lowed by single point calculations with the 6-31G(d) basis set.
The three-dimensional structure of the W-oxo-dimer of hematin had
to be modeled, because it has not been resolved experimentally. A
conformational search was ¢rst performed using the CHARMM force
¢eld [27,28] to ¢nd out the most likely position of the porphyrin
subunits relative to each other, as well as the propionic and vinyl
substituents. A geometry optimization was then carried out with the
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AM1(d) semi-empirical method [29,30] and the resulting neutral struc-
ture was further subjected to a single point calculation using DFT
with the B3LYP functional and the 6-31G(d) basis set.
The three-dimensional structure of the hemozoin dimer was ob-
tained from the Cambridge Crystallographic Database [6]. The struc-
ture was further subjected to a single point calculation using DFT
with the B3LYP functional and the 6-31G(d) basis set.
Both hemozoin and the W-oxo-dimer of hematin show a spin state
of 5/2, as determined by Mo«ssbauer spectroscopy [31]. This was the
value considered in the calculations performed on the hematin com-
plexes.
All ab initio calculations were performed with the Gaussian 98
package [32].
Molecular electrostatic potential surfaces were drawn using the CU-
BEGEN utility present in Gaussian 98 [32], applied to the optimized
geometries of all molecules. The visualization of all quantum calcu-
lations results was performed with Molekel 4.2 [33].
The docking procedure was performed with GOLD-Genetic Opti-
mization for Ligand Docking, using both scoring functions (Gold-
score and Chemscore) included in the software [34^39]. The Goldscore
¢tness function has four components: protein^ligand bond energy,
protein^ligand van der Waals energy, ligand internal van der Waals
energy, and ligand torsional strain energy. This ¢tness function has
been optimized for the prediction of ligand binding positions. The
Chemscore function was derived empirically from a set of 82 pro-
tein^ligand complexes for which measured binding a⁄nities were
available. This function estimates the total free energy that occurs
in ligand binding as a summation of several physical contributions:
hydrogen bonding, metal binding, lipophilic terms, rotatable bond
freezing terms. The ¢nal Chemscore value is obtained by adding in
a clash penalty and internal torsion terms. GOLD constitutes one of
the most respected programs for docking studies [38,39]. The applica-
tion of this method was performed with the active molecules and
receptors in the protonation state that occurs with the pH conditions
inside the parasite vacuole [6,40,41]. The work was performed in the
standard default settings for the best possible predictive accuracy,
with 10 docking runs for each ligand. Visualization of docking results
was performed with DS ViewerLite from Accelrys.
3. Results and discussion
3.1. Molecular electrostatic potential calculations
Three-dimensional surfaces of molecular electrostatic po-
tentials at the constant values of 310 kcal/mol and 10 kcal/
mol were generated to determine the pro¢le of the electro-
static potential of a compound when approaching another
molecule. These surfaces allow the determination of points
of possible interaction based on the concept of electrostatic
interactions. The quantities of 310 kcal/mol and 10 kcal/mol
correspond to limit values de¢ning a long-range interaction.
The de¢nition of isosurfaces using other values does not show
any signi¢cant di¡erences.
The study of the electrostatic properties of the W-oxo-dimer
of hematin shows that the most negative potential is located
on the central part of the complex, corresponding to the iron
atoms and the tetrapyrrole system, with the most positive
potential found in the surrounding area. The carboxyl oxygen
atoms also present negative electrostatic potential (Fig. 1).
This pro¢le is represented by electrostatic potential isosurfaces
at values of 310 kcal/mol, with a large surface centered on the
dimer, corresponding to the system containing the iron, oxy-
gen bridge and the pyrrolic nitrogen atom system. Smaller
surfaces can be found over the carboxylic oxygens. The area
around these surfaces corresponds to a positive electrostatic
potential.
Fig. 1. Three-dimensional electrostatic potential isosurface at 310 kcal/mol (black chickenwire) and 10 kcal/mol (light gray transparent £at-
shade) for hematin W-oxo-dimer and hemozoin (side view and top view).
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Observing the distribution of electrostatic potential in this
receptor, we can de¢ne a possibility of attachment with an
active molecule, based on the concept of complementary elec-
trostatic pro¢les. The active compound should present a cen-
tral point of positive potential and peripheral points of neg-
ative potential. The central point of positive potential would
interact with the negative central zone of the hematin dimer,
with the peripheral points of negative potential interacting
with the peripheral positive area of this receptor. As a con-
sequence, the iron(III) atoms would not be available to estab-
lish a coordination bond with a propionic chain from another
hematin unit, inhibiting the formation of hemozoin.
The observation of the electrostatic potential isosurfaces at
values of 310 kcal/mol of hemozoin denotes the presence of a
negative value of potential at the points of carboxylate^iron
(III) coordination, with a peripheral positive potential (Fig. 1).
The previous considerations about the possibility of associ-
ation between the hematin W-oxo-dimer putative receptor and
an active compound are also applicable to hemozoin.
The antimalarial compounds can therefore act by stabilizing
the receptor due to the electrostatic interactions determined
by their complementary electrostatic pro¢les, avoiding a fur-
ther uptake of hematin in the aggregation phenomenon.
The observation of the electrostatic pro¢les of the inhibitors
of hematin aggregation is in accordance with the complemen-
tarity-based possibility of drug^receptor association (Fig. 2).
These compounds present a null or positive potential placed
over at least a part of the aromatic rings, complemented by
the existence of peripheral bulks of negative potential [22^26].
3.2. Docking studies
The docking study was performed to predict how the po-
tential antimalarial molecules presented here would bind to
both putative receptors, by using a non-deterministic sampling
method. The GOLD algorithm performs a stochastic search
for preferred orientation and conformation of the ligand in
relation to the receptor [38].
The calculations were performed on the receptors in the
deprotonated form, which is the form that occurs in vivo
[6]. The results presented here correspond to the best-scored
solutions of docking for each structure. Both scoring func-
tions present in GOLD were used. The results obtained with
Goldscore and Chemscore for the studied compounds corre-
lated with the complementarity of the electrostatic potentials.
The association of all 4-aminoquinolines with the hematin
W-oxo-dimer gave similar results for both scoring functions.
The area around the amino group connected to the quinolinic
ring, corresponding to a positive electrostatic potential, inter-
acts with the central negative zone of the hematin dimer. The
negative potential located over the aromatic area interrelates
with the peripheral positive area of the W-oxo-dimer receptor
(Fig. 3a).
Fig. 2. Three-dimensional electrostatic potential isosurfaces at 310 kcal/mol (dark gray transparent £atshade) and 10 kcal/mol (light gray trans-
parent £atshade) for compounds that present antimalarial activity as an inhibition of hematin aggregation.
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Halofantrine presents two ways of associating with the
hematin W-oxo-dimer, both agreeing with the complementarity
of electrostatic pro¢les. In the Chemscore result the negative
central area of the hematin complex interacts with the positive
aromatic rings of the drug (Fig. 3b). For the Goldscore func-
tion, the iron^tetrapyrrole system interacts with the hydroxyl
group of halofantrine (Fig. 3c). Me£oquine and quinine also
present an association between their hydroxyl group and the
hematin dimer iron^tetrapyrrole system (Fig. 3d,e). The struc-
tural components corresponding to the peripheral bulks of
Fig. 3. Docking results (top view) for: (a) chloroquine over hematin W-oxo-dimer, with Chemscore; (b) halofantrine over hematin W-oxo-dimer,
with Chemscore; (c) halofantrine over hematin W-oxo-dimer, with Goldscore; (d) me£oquine over hematin W-oxo-dimer, with Goldscore; (e)
quinine over hematin W-oxo-dimer, with Chemscore; (f) 4,5-dihydroxyxanthone over hematin W-oxo-dimer, with Goldscore; (g) 2,3,4-trihydroxy-
xanthone over hematin W-oxo-dimer, with Chemscore; (h) mepacrine over hemozoin, with Chemscore; (i) 4,5-dihydroxyxanthone over hemo-
zoin, with Chemscore; (j) 2,3,4,5,6-pentadihydroxyxanthone over hemozoin, with Chemscore; (k) 2,3,4,5,6-pentahydroxyxanthone over hemo-
zoin, with Goldscore; (l) 2,3,4,5,6,7-hexahydroxyxanthone over hemozoin, with Goldscore.
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negative potential interact with the zone of positive potential
of the hematin W-oxo-dimer. These results show the in£uence
of the hydroxyl group in the action of halofantrine, me£o-
quine and quinine.
The interaction pro¢le of the hydroxylated xanthones is
also based on electrostatic complementarity, de¢ned between
the central aromatic area of the xanthone derivatives, with
positive potential, and the central area of the W-oxo-dimer
receptor, with negative potential (Fig. 3f). In addition, the
Chemscore function de¢ned the hydrogen bonding of the hy-
droxyl groups in positions 3 and 4 of the xanthone nucleus to
one of the carboxyl groups of the hematin subunit (Fig. 3g).
The observation of the stereoelectronic pro¢le for the active
xanthones shows that the hydroxyl in position 4 is always
present, reinforcing the importance of this substituent.
In all results obtained on the hematin W-oxo-dimer, the iron
atom is protected from coordination with a propionic chain of
another hematin, avoiding further aggregation to hemozoin
crystallites.
The docking with hemozoin occurred laterally to the car-
boxylate^iron(III) coordination system. The association of
4-aminoquinolines me£oquine, halofantrine and quinine hap-
pened in the same way as mepacrine, presented in Fig. 3h.
These docking solutions are also coherent with the concept of
complementarity of electrostatic potentials. The interaction
occurs between the negative area over the carboxylate^iron
(III) system of hemozoin and the area of positive potential
of the drug (corresponding to the zone around the connection
of the side chain to the aromatic ring-conjugated system).
These results do not show how the inhibition of new hematin
uptake would occur.
The hydroxylated xanthones also presented di¡erent results
for each scoring function, for hemozoin. In the Chemscore
results, the xanthone derivatives associated with the carboxyl
groups by hydrogen bonding as presented in Fig. 3i. The
Goldscore function produced di¡erent results, but also with
hydrogen bonding with a carboxyl group (Fig. 3j). With this
scoring function, the hydroxylated xanthones are placed side
by side with the carboxylate^iron(III) coordination system,
except for 4,5-dihydroxyxanthone and 2,3,4,5,6,7-hexahydroxy-
xanthone, which gave similar results for both scoring func-
tions. 4,5-Dihydroxyxanthone did not establish hydrogen
bonds (Fig. 3k). 2,3,4,5,6,7-Hexahydroxyxanthone established
hydrogen bonds with both carboxyl groups of one of the
hematin subunits of hemozoin (Fig. 3l). This hydrogen bond-
ing can interfere with the carboxylic groups’ availability to
coordinate with an iron atom of other hematin molecule.
The present communication suggests that the association
between active molecules and their receptor can be ruled by
the complementarity of electrostatic potentials. The results of
the docking studies performed agreed with the opposite dis-
tribution of electrostatic potential between the receptors and
the active compounds. Furthermore, the orientation results
obtained with the docking process are in agreement with the
nuclear magnetic resonance work performed with chloroquine
and quinine [8,42]. The docking studies can be of great help in
the design of new structures, which could be applicable in the
inhibition of hemozoin crystallites formation. The design of
new potential antimalarials based on this information is under
way [43]. These new molecules are chlorinated xanthones and
present a stereoelectronic pro¢le comparable to the electro-
static properties of the compounds presented in this study.
We have included such two examples in Fig. 4. We are hope-
ful that, under their action, the resultant free hematin will
develop its toxic activity against the Plasmodium parasite,
producing the antimalarial action.
4. Supporting information
Three-dimensional electrostatic potential isosurfaces and
docking visual results for all compounds studied have been
presented as the article’s supporting information.
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